Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)

Gut

Volumn 68, Issue 1, 2019, Pages 40-48

  Danese, Silvio ^a   Vermeire, Séverine ^b   Hellstern, Paul ^c   Panaccione, Remo ^d   Rogler, Gerhard ^e   Fraser, Gerald ^f   Kohn, Anna ^g   Desreumaux, Pierre ^h   Leong, Rupert W ⁱ   Comer, Gail M ^j   Cataldi, Fabio ^j   Banerjee, Anindita ^j   Maguire, Mary K ^j   Li, Cheryl ^j   Rath, Natalie ^j   Beebe, Jean ^j   Schreiber, Stefan ^k  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Nature Coast Clinical Research   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f TEL AVIV UNIVERSITY   (Israel)

^g UOC Gastroenterologia Riabilitativa   (Italy)

^h UNIVERSITÉ DE LILLE   (France)

ⁱ Department of Microbiology and Infectious Diseases   (Australia)

^j PFIZER INC   (United States)

^k UNIVERSITY OF KIEL   (Germany)

more..

Author keywords

anti IL6 antibody; anti TNF; Crohn's disease; inadequate response

Indexed keywords

INTERLEUKIN 6 ANTIBODY; PF 04236921; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PF-04236921;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CONSTIPATION; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTALGIA; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ADOLESCENT; AGED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85045846875     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2017-314562     Document Type: Article

References (14)

1. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
3. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
4. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83.
5. Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther 2016;43:30-51.
6. Allocca M, Jovani M, Fiorino G, et al. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr Drug Targets 2013;14:1508-21.
7. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96.
8. Fogel R, Sridharan S, Li C, et al. AB0724 Safety, pharmacokinetics, and pharmacodynamics of a human anti-IL6 monoclonal antibody PF-04236921 in healthy subjects. Ann Rheum Dis 2013;71 (Suppl.3):680.
9. Wallace DJ, Strand V, Merrill JT, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis 2017;76:534-42.
10. Curtis JR, Perez-Gutthann S, Suissa S, et al. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum 2015;44:381-8.
11. Gout T, Ostör AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 2011;30:1471-4.
12. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn's disease. Am Fam Physician 2011;84:1365-75.
13. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
14. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med 2016;375:1946-60.